XML 14 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Income - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Net revenues $ 5,065 $ 5,650
Cost of sales 2,717 2,811
Gross profit 2,348 2,839
Research and development expenses 317 432
Selling and marketing expenses 771 958
General and administrative expenses 329 366
Other asset Impairments, restructuring and other items 707 240
Goodwill impairment 180  
Legal settlements and loss contingencies (1,278) 20
Other income (203) (72)
Operating income 1,525 895
Financial expenses, net 271 207
Income before income taxes 1,254 688
Income taxes 46 54
Share in (profits) losses of associated companies, net 74 (7)
Net income 1,134 641
Net Income (loss) attributable to non-controlling interests 14 (4)
Net income attributable to Teva 1,120 645
Dividends on preferred shares 65 65
Net income attributable to ordinary shareholders $ 1,055 $ 580
Earnings per share attributable to ordinary shareholders:    
Basic $ 1.04 $ 0.57
Diluted $ 1.03 $ 0.57
Weighted average number of shares (in millions):    
Basic 1,017 1,016
Diluted 1,020 1,017